Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15319052 | 0.88 | CCR2 (0.78) | CCR2KCNH2 | |
| SCHEMBL14636914 | 0.87 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL15320174 | 0.87 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL15319999 | 0.87 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL19337900 | 0.87 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL19337815 | 0.87 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL16577088 | 0.87 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL15320653 | 0.87 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL15319768 | 0.87 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL15320681 | 0.87 | CCR2 (1.00) | CCR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2834234-B1 | FUSED CYCLOPENTYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-13 | — | — | EP | disclosed |
| EP-2834234-B1 | FUSED CYCLOPENTYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-13 | — | — | EP | disclosed |
| US-9150532-B2 | Fused cyclopentyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-06 | — | — | US | disclosed |
| US-9150532-B2 | Fused cyclopentyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-06 | — | — | US | disclosed |
| US-20150080588-A1 | FUSED CYCLOPENTYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (US) | 2015-03-19 | — | — | US | disclosed |
| US-20150080588-A1 | FUSED CYCLOPENTYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (US) | 2015-03-19 | — | — | US | disclosed |
| US-8822460-B2 | Fused cyclopentyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-02 | — | — | US | disclosed |
| US-8822460-B2 | Fused cyclopentyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-02 | — | — | US | disclosed |
| US-20140018356-A1 | FUSED CYCLOPENTYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA, NV (BE) | 2014-01-16 | — | — | US | disclosed |
| US-20140018356-A1 | FUSED CYCLOPENTYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA, NV (BE) | 2014-01-16 | — | — | US | disclosed |
| WO-2013152269-A1 | FUSED CYCLOPENTYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018356-A1 | FUSED CYCLOPENTYL ANTAGONISTS OF CCR2 | CCR2, CCR5, CCR1 | CCR2 1/4885KCNH2 1910/4885 |
| US-20150080588-A1 | FUSED CYCLOPENTYL ANTAGONISTS OF CCR2 | CCR2, CCR5, CCR1 | CCR2 1/4885KCNH2 2262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.